LMR Partners LLP Buys Shares of 229 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

LMR Partners LLP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 229 shares of the biopharmaceutical company’s stock, valued at approximately $241,000.

A number of other large investors have also made changes to their positions in the stock. GLOBALT Investments LLC GA boosted its stake in shares of Regeneron Pharmaceuticals by 1.5% during the third quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock valued at $1,122,000 after acquiring an additional 16 shares during the last quarter. Quest Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 391.0% during the third quarter. Quest Partners LLC now owns 1,974 shares of the biopharmaceutical company’s stock valued at $2,075,000 after acquiring an additional 1,572 shares during the last quarter. AMG National Trust Bank boosted its stake in shares of Regeneron Pharmaceuticals by 14.6% during the third quarter. AMG National Trust Bank now owns 220 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 28 shares during the last quarter. Swiss National Bank boosted its stake in shares of Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Regeneron Pharmaceuticals by 16.7% during the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock valued at $9,587,000 after acquiring an additional 1,306 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $743.35 on Thursday. The company has a market cap of $81.69 billion, a P/E ratio of 18.40, a PEG ratio of 2.86 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $736.01 and a one year high of $1,211.20. The business’s 50-day simple moving average is $961.76 and its 200 day simple moving average is $1,030.14.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on REGN shares. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Oppenheimer decreased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Finally, Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.